Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Lead Sponsor

Merck Sharp & Dohme LLC

Age

45 - 85 years

Sex

FEMALE

Healthy Volunteers

No

•Participant has been postmenopausal for 3 years
•Participant has BMD t-score at the total hip, hip trochanter, femoral neck, or lumbar spine ≥ -1.5 but \> -3.5
•Participant has 2 hips that are evaluable by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), e.g. contain no hardware from orthopedic procedures
•Participant is ambulatory

•Participant has had a previous hip fracture
•Participant has had \>1 prior clinical vertebral fracture AND is a candidate for osteoporosis therapy
•Participant has been treated with oral bisphosphonates, strontium, parathyroid hormone (PTH) or other agents with an effect on bone
•Participant has had metabolic bone disorder other than osteoporosis
•Participant has renal stones, Parkinson's disease, multiple sclerosis (MS) or active parathyroid disease.